Abstract 3900: Discovery of FQIT: An imidazo[5,1- f ][1,2,4]triazine derived dual IGF-1R/IR inhibitor

• Published in: Cancer research (Chicago, Ill.) Vol. 72; no. 8_Supplement; p. 3900
• Main Authors: Jin, Meizhong, Gokhale, Prafulla, Cooke, Andy, Foreman, Kenneth, Buck, Elizabeth, May, Earl, Feng, Lixing, Bittner, Mark, Kadalbajoo, Mridula, Landfair, Darla, Siu, Kam, Stolz, Kathryn, Werner, Douglas, Laufer, Radoslaw, Li, An-Hu, Dong, Hanqing, Steinig, Arno, Kleinberg, Andrew, Yao, Yan, Pachter, Jonathan, Wild, Robert, Mulvihill, Mark
• Format: Journal Article
• Language: English
• Published: 15.04.2012
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2012-3900

Abstract Insulin-like growth factor-1 receptor (IGF-1R) has been recognized as a major target in cancer drug discovery due to its strong implications in various stages of tumorigenesis based on accumulated preclinical data over the years. Recent research on compensatory crosstalk between IGF-1R and insulin receptor (IR) signaling pathways suggests that targeting both receptors is critical to fully blocking the IGF signaling axis. Therefore, inhibition of both receptors is anticipated to result in a more therapeutically beneficial response than targeting IGF-1R alone (e.g. IGF-1R specific antibodies). These findings provided the biological rationale as well as set the foundation for the pursuit and ultimate discovery of OSI-906 (linsitinib), a small molecule dual IGF-1R/IR inhibitor currently in clinical development. As part of OSI's ongoing investment in a small molecule drug discovery platform targeting IGF-1R and IR, a new series of potent and selective imidazo[5,1-f][1,2,4]triazine derived inhibitors of IGF-1R and IR have been identified. Structure-activity relationships and optimization driven by structure-based drug design (SBDD) leading to the discovery of FQIT, a potent, highly selective, well-tolerated and orally bioavailable dual inhibitor of IGF-1R and IR with in vivo efficacy in multiple tumor xenograft models will be discussed. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3900. doi:1538-7445.AM2012-3900